king's college hospital clinical research facility

Cookies: How we use information on our website:

We use cookies on our website to make it clear, useful and reliable.In order to achieve this and to provide certain personalised features we store a small amount of data about you. To learn more visit Cookies: How we use the information on our website. By navigating from the front page to other sections of our website, you are consenting to information being stored.

Our world-class facilities are open to researchers from academia and industry

Our policies and operating procedures

Meet our staff

King's CRF Nurse Team Lead: Why I love research

Empowering voices: A public member's story in the fight against Mouth Cancer

International Stress Awareness Week: Insights from a public member

Apply to use the King's CRF

What we offer

Get involved

News and events

The   NIHR Maudsley Biomedical Research Centre (BRC)   is part of the   NIHR   and hosted by   South London and Maudsley NHS Foundation Trust   in partnership with   King's College London . We are part of  King’s Health Partners Academic Health Sciences Centre .  

© NIHR Maudsley Biomedical Research Centre 2024 | Website design by   CSMB Design  | All rights reserved.

• Education and Resources
• Clinical Academic Excellence
• News and Events
• Neurosciences
• Cardiovascular
• About KHP Haematology
• Patient engagement

Research and innovation

• Education and training
• King’s College Denmark Hill Haematology Biobank
• Diabetes, Endocrinology and Obesity
• Women and Children's Health
• Behavioural and Developmental Psychiatry
• Child and Adolescent Mental Health
• Critical Care and Anaesthetics
• Genetics, Rheumatology, Infection, Immunology and Dermatology
• Imaging and Biomedical Engineering
• Liver, Renal, Urology, Transplant, Gastro/Gastro Intestinal Surgery
• Medicine and Integrated Care
• Mental Health of Older Adults and Dementia
• Orthopaedics, Trauma and Plastics
• Palliative Care
• Pharmaceutical Sciences
• Psychological Medicine and Integrated Care
• Respiratory and Allergy

Our CAP provides a patient-centred research programme with two integrated clinical trial research units, so patients from across the region have access to many of the latest treatments and developments. 

Research teams across King’s Health Partners Haematology have demonstrated continued success in being the first to recruit to multiple competitive global trials, and leading recruitment to many national and international clinical trials. We also work closely with commercial partners to host national and international clinical trials as well as funded Investigator Initiated Trials. 

Our haematology clinical trials and research studies are delivered by dedicated research teams in the following units: 

• Haematology Research Unit at King’s College Hospital NHS Foundation Trust 
• Oncology and Haematology Clinical Trials Unit at the Cancer Centre at Guy’s and St Thomas’ NHS Foundation Trust 

We also have access to state-of-the art research facilities at  

• NIHR King’s Clinical Research Facility at King’s College Hospital NHS Foundation Trust 
• NIHR Clinical Research Facility at Guy’s and St Thomas’ NHS Foundation Trust; the only Medicines and Healthcare products Regulatory Agency (MHRA) phase I accredited NHS-managed CRF in London. 
• The Cell Therapy Unit within the NIHR King’s Clinical Research Facility  
• The Gene Therapy Vector Facility at King’s College London 

Current clinical trials 

Please follow the links below for details of current trials across our specialisms: 

• Cellular and transplant therapy  
• Classical haematology  
• Lymphoid leukaemia’s and lymphoma  
• Myeloid disorders  
• Plasma cell disorders  
• Red cell disorders  
• Thrombosis and haemostasis  

Health Digital and Data Sciences 

The  South East London Plasma Cell Disorders Registry (SEL PCD Registry)  is a research database collecting information on patients with a range of plasma cell disorders. 

Achievements 

We have secured funding through competitive open-call research bids from pharmaceutical, biotech, government and charity funding bodies to enable pre-clinical research and its translation, including first-in-human (phase 1) trials and later phase clinical trials. 

Our research has been published in peer reviewed journals including New England Journal of Medicine, the Lancet, Nature, Journal of Clinical Oncology, Blood and many others, demonstrating the extensive and innovative research taking place across our CAP. We are making significant contributions to the ever-evolving body of knowledge and helping advance care and treatment options for our patients.  

Examples of success include: 

• King’s College Hospital NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust have been awarded funding and are accredited IMPACT and TAP Centres; these are accelerated research platforms for the development and delivery of pioneering clinical trials in stem cell transplant (IMPACT) and blood cancers (TAP). 
• We play an internationally leading role in the development of molecular monitoring techniques for acute myeloid leukaemia. This has led to the establishment of an international reference laboratory for patients treated in and outside clinical trials, opening the door to truly personalised therapy.  
• Our myeloproliferative neoplasms service is an international centre of excellence and work here has led to the discovery of driver mutations and delivery of targeted therapies, which are now approved. We continue to provide global leadership of cutting edge commercial and academic trials. We have led the world literature for management of pregnancy and young patients with these conditions. 
• The Cell and Gene Therapy at King’s College London produces the largest number of lentivirus and retrovirus (gene carriers) based vectors for regulatory approved clinical trials in Europe. 
• King’s College Hospital NHS Foundation Trust’s Haematology department is one of the first accredited CAR-T centres in the UK offering commercial CAR-T products (a type of immunotherapy which involves collecting and using the patients' own immune cells to treat their condition) for cancer treatment, as well as several CAR-T trials for a range of haematological malignancies. 

Read our  latest news  and learn more about  upcoming events . 

To get in touch with the Team and learn more about our work, please email  [email protected] .  

The South East London Plasma Cell Disorders Registry

The South East London Plasma Cell Disorders Registry (SEL PCD Registry) is a research database collecting information on patients with a range of plasma cell disorders including 

• Myeloma 
• Monoclonal gammopathies 
• AL amyloidosis 
• POEMS syndrome 
• Solitary plasmacytomas 
• IgM neuropathy 

The Registry is a collaborative project initiated by King’s Health Partners (King’s College Hospital and Guys and St Thomas’ Hospitals), and Lewisham and Greenwich NHS Trust. The information we gather is being made available for quality improvement audits and research studies. 

Data summary 

The Registry collects routine clinical data from existing patient records, without any additional procedures or data collection exercises for patients. Data collected include: 

Basic demographic details such as gender, age, and ethnicity: Relevant diagnostic details Information on all treatments administered, including chemotherapy, radiotherapy, stem cell transplant, and spinal surgery Response, progression, and toxicity details, to judge treatment effectiveness  

Consent and confidentiality 

We are inviting all patients with plasma cell disorders under the care of one of the participating sites to enrol in the registry. The data that we collect on consenting patients is pseudonymised and stored securely. This means any direct identifiers (names, NHS numbers, addresses, etc) are removed to protect patient confidentiality. Registry governance 

A Registry Oversight Committee meets twice yearly to review Registry activities. The Committee comprises the lead consultant from each participating site alongside patient representatives, Information Governance experts, and other interested parties. The Committee monitors data collection, reviews requests for data use, and oversees the publication of findings. 

Data use 

All requests for data to complete audits and research studies are tracked, reviewed, and approved by the Registry Oversight Committee. Audits are internal reviews of data conducted by NHS Trusts, and are therefore required to meet the initiating Trusts’ standards of data protection and scientific rigour. 

Research studies are those that originate from within or without the Trust with the aim of publication, usually in a medical or scientific journal. These studies will inform the development of future care. All proposed research projects are required to demonstrate orientation towards patient benefit, ensure potential ethical issues have been thought through and mitigated, and must display statistical / scientific viability of expected outcomes. 

All patient data supplied to researchers or for audits is fully anonymised to protect patient confidentiality. For more details or to enrol in the Registry, please contact  [email protected] .  

Want to know more?

© King's Health Partners 2024

We use cookies on our website to provide a better service. By continuing to browse this site you are agreeing to our use of cookies. How to manage your cookie settings .

King’s College Hospital

The King’s MND Care and Research Centre is a multidisciplinary team of clinical and research staff, seeing about 200 new patients a year, providing state of the art care coupled with access to cutting edge research to accelerate the search for a cure.

The King’s MND Care and Research Centre is a multidisciplinary team of clinical and research staff, funded by the NHS, government grants and charity grants. We see about 200 new patients a year, with a further 400 follow-up slots in neurology and hundreds more in related services as needed. Our teams include neurology, respiratory, nutritional and palliative medical and allied health professional staff, with clinical trials teams, laboratory researchers and statistical and computing expertise. We provide state-of-the-art care coupled with access to cutting edge research. We aim to accelerate the search for a cure by combining clinical care with clinical research, and collaborate internationally to increase our chances of success.

Our Specialists

Ammar al-chalabi.

Professor Ammar Al-Chalabi is head of the Basic and Clinical Neuroscience Department at […]

James Bashford

Dr James Bashford graduated from Cambridge University Medical School in 2010. After […]

Current trials

Fusion trial, phoenix trial, adore trial.

Search form

• About Synnovis
• Departments and laboratories
• Our services
• Phlebotomy training
• Primary and Community Care
• Test information
• Secondary Care NHS Trusts
• Private Users
• News and press
• Articles and papers
• Synnovis Policies, User Guides and Documents
• Transformation
• Your career
• Working with us
• Career pathways
• Current vacancies
• Training and development
• Key contacts
• Customer service
• Synnovis Service Updates
• Welcome, Sign in or Register

Clinical Biochemistry Laboratory at King's College Hospital

We are a UKAS accredited medical laboratory no.9067 providing a high quality, comprehensive range of routine diagnostic and specialist biochemical testing in a newly refurbished state of the art laboratory.

We perform about 4 million tests per year for the hospital and surrounding community; 80% are of a routine diagnostic nature and 20% of a highly complex and specialised nature.

Key features:

• We undertake testing for applied and contracted biomedical research.
• We are a centre for training in metabolic medicine for medical graduates and for all grades of laboratory staff and have developed a comprehensive training schedule including mentoring and e-learning facilities.
• We provide a comprehensive pre- and post-investigation consultation and interpretation of results for hospital medical staff and general practitioners.
• A large automated section of the laboratory is dedicated to performing routine diagnostic tests. We have recently further increased our capacity and efficiency levels for such routine testing, with the opening of our newly completed, state-of-the-art Blood Sciences Laboratory.
• We have a strong emphasis on NHS research and development, which under the lead of Professor Roy Sherwood, consultant clinical scientist, evaluates new assays and offers contract research.
• We have an established track record of supporting clinical and research trials for institutions from both the public and private sector. We are currently involved with major global pharmaceutical companies and research institutions in collaborative projects.
• Teaching and training of staff is of high importance and several staff have undertaken research projects for Royal College accreditation, MSc and PhD levels and we support laboratory based projects for undergraduates and post-graduate students as well as visiting students from overseas. 

Blood Sciences test list

 See attachment below for our most up to date test repertoire

Chemistry critical results phoning limits 

Please see the list of critical chemistry results for phoning 

Clinical Biochemistry - Blood Sciences at King's College Hospital

Last updated: 14/01/2014

eMail alerts and news

Twitter LinkedIn RSS

Site details

• Privacy, data and cookie policy
• Terms of use
• Accessibility

Working with our NHS service partners to set the standard for the future of pathology

Viapath is a founding member of The Association of Independent Pathology Providers (AIPP), which is a trade association representing innovative research-based diagnostic testing companies. 

Copyright 2014-2024 Synnovis Group LLP. Synnovis, the Synnovis logo and Nutris are registered trademarks of Synnovis Group LLP.

The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions

Affiliations.

• 1 National Heart and Lung Institute, Imperial College London, London, UK.
• 2 School of Public Health, Imperial College London, London, UK.
• 3 NIHR Imperial Biomedical Research Centre, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
• 4 NIHR Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
• 5 NIHR King's Biomedical Research Centre, King's College London and King's College Hospital NHS Foundation Trust, London, UK.
• 6 NIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
• 7 Institute of Health Informatics, University College London, London, UK.
• 8 Imperial Clinical Analytics, Research & Evaluation (iCARE) and Department of Surgery & Cancer, Imperial College London, London, UK.
• 9 Early Diagnosis and Detection Centre, NIHR BRC at The Royal Marsden and Institute of Cancer Research, London, UK.
• 10 NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
• 11 NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust and the University of Manchester, Manchester, UK.
• 12 NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
• 13 NIHR Leicester Biomedical Research Centre, Glenfield Hospital, and Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
• 14 NIHR Bristol Biomedical Research Centre, University of Bristol and University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
• 15 NIHR Guys & St Thomas' Hospital Clinical Research Facility, King's College Hospital, and King's College London British Heart Foundation Centre of Excellence, London, UK.
• PMID: 37955026
• PMCID: PMC10637362
• DOI: 10.2147/COPD.S432166

Background: No single biomarker currently risk stratifies chronic obstructive pulmonary disease (COPD) patients at the time of an exacerbation, though previous studies have suggested that patients with elevated troponin at exacerbation have worse outcomes. This study evaluated the relationship between peak cardiac troponin and subsequent major adverse cardiac events (MACE) including all-cause mortality and COPD hospital readmission, among patients admitted with COPD exacerbation.

Methods: Data from five cross-regional hospitals in England were analysed using the National Institute of Health Research Health Informatics Collaborative (NIHR-HIC) acute coronary syndrome database (2008-2017). People hospitalised with a COPD exacerbation were included, and peak troponin levels were standardised relative to the 99th percentile (upper limit of normal). We used Cox Proportional Hazard models adjusting for age, sex, laboratory results and clinical risk factors, and implemented logarithmic transformation (base-10 logarithm). The primary outcome was risk of MACE within 90 days from peak troponin measurement. Secondary outcome was risk of COPD readmission within 90 days from peak troponin measurement.

Results: There were 2487 patients included. Of these, 377 (15.2%) patients had a MACE event and 203 (8.2%) were readmitted within 90 days from peak troponin measurement. A total of 1107 (44.5%) patients had an elevated troponin level. Of 1107 patients with elevated troponin at exacerbation, 256 (22.8%) had a MACE event and 101 (9.0%) a COPD readmission within 90 days from peak troponin measurement. Patients with troponin above the upper limit of normal had a higher risk of MACE (adjusted HR 2.20, 95% CI 1.75-2.77) and COPD hospital readmission (adjusted HR 1.37, 95% CI 1.02-1.83) when compared with patients without elevated troponin.

Conclusion: An elevated troponin level at the time of COPD exacerbation may be a useful tool for predicting MACE in COPD patients. The relationship between degree of troponin elevation and risk of future events is complex and requires further investigation.

Keywords: COPD; CVD; exacerbation.

© 2023 Kallis et al.

• Cardiovascular Diseases* / etiology
• Hospitalization
• Patient Readmission
• Pulmonary Disease, Chronic Obstructive*

Grants and funding

• CH/16/1/32013/BHF_/British Heart Foundation/United Kingdom
• SP/17/16/33519/BHF_/British Heart Foundation/United Kingdom

Section menu +

• Corporate publications
• Data protection
• Emergency preparedness reporting
• Willowfield Building
• FOI appeal procedure
• FoI frequently asked questions
• Publication of FoI request handling statistics
• Publication of spend
• NHS Oversight Framework
• Bribery Act statement
• Mortality monitoring
• Nursing and Midwifery staffing levels
• Patient Safety Incident Response Framework (PSIRF)
• Privacy and dignity
• Safeguarding adults
• Safeguarding children
• Have your say
• Our helipad
• Support services
• Trade Union Facility Time
• Epic launch - information for patients
• Your data and Epic
• Anti-discrimination statement
• Equality, diversity and inclusion reporting
• Annual Members' Meeting
• King's Critical Care - Carers' Cafe
• King's Critical Care Pathfinder Group
• King's Intensive Care Unit (ICU) Recovery Group
• Kingfishers
• Partner charities
• Volunteering
• Board papers
• Executive Directors
• Non-executive Directors
• Council of Governors minutes and agendas
• Governor Election
• Nominated governors
• Patient governors
• Public governors
• Staff governors
• Inside King’s magazine
• Brilliant people
• King's Anchor Programme
• King’s Green Plan
• Partnership working
• Questionnaires to monitor your progress
• The King's story
• Filling out your application
• Before you start
• Contact the Recruitment team
• Recruitment events
• Assessment centres
• Tips for a successful interview
• Starting at King’s
• Breast Radiology continuing professional development
• Breast radiology postgraduate programme
• MSc in Medical Engineering and Physics
• Structured Training and Education for Pharmacists (STEP)
• Dental Team Education Centre
• CPPD funding for non-medical staff
• Harkness Fellowships
• King’s College Hospital Nurses’ League grants
• The Health Foundation Quality Improvement Fellowship
• Mandatory and statutory training
• Postgraduate Medical and Dental Education
• Newly qualified nurses and midwives - Preceptorship
• Professional staff
• Student nursing and midwifery
• Flexible working
• Health Service Discounts
• Salary sacrifice schemes
• Season ticket loan scheme
• Pay, pension and leave
• Staff accommodation
• Buddy Scheme
• Employee Assistance Programme (EAP)
• Equality, diversity and inclusion in the workplace
• Occupational Health and Wellbeing
• Support to stop smoking
• Nutrition and Dietetics
• Occupational Therapy
• Radiography
• Speech and Language Therapy
• Apprenticeships
• Healthcare Assistants and Clinical Support Workers
• Staff bank for doctors
• Staff bank for nurses and all other staff
• Return to practice
• Work experience
• COVID-19 (coronavirus)
• Current vacancies
• Document library
• Grand Rounds
• Upcoming events
• GP frequently asked questions
• Medicines Formulary
• IENFD for Small Fibre Neuropathy
• Molecular Neuropathology Service
• Muscle and nerve biopsy protocol
• Neuropathology contact details
• Services overview
• Turnaround times for samples
• Pathology contact details
• Requesting tests
• Sample packaging requirements
• Transport of samples to Synnovis
• Patient transport
• Primary Care Liaison Service
• e-Referral Service
• Emailing referrals
• Acute liver inpatient referrals
• Acute neurosurgery referrals
• Major trauma referrals
• Urgent suspected cancer referrals
• Referral forms
• South East London and Kent Spinal Network
• Virology guide for GPs
• Birth choices
• Book your maternity care with us
• Contact the maternity team
• Maternity leaflets and resources
• Maternity research
• Maternity voices
• Our maternity locations
• Blood pressure clinic
• Maternal medicine
• Mental health in pregnancy
• Pregnancy loss
• Condition checks
• Contacting the Media team
• Dealing with major incidents
• Photography and filming requests
• King's buildings
• Parking frequently asked questions
• Public transport
• Accessible Information Standard
• Interpreting
• Learning disabilities
• Macmillan Information and Support Centre
• Making a complaint
• Critical care patients
• Day surgery patients
• Dental patients
• Emergency patients
• During your stay
• When you leave
• Data and security
• Proxy access for parents and carers
• Sexual health records
• Sign up to MyChart
• Test results
• Ongoing therapies and recovery
• After your appointment
• Outpatient appointments
• Video appointments
• When you arrive
• Overseas visitors
• Patient information leaflets
• Pre-operative assessment clinic
• Private patients
• Online booking system for outpatient blood tests
• Medical Records
• London Care Record
• London Care Record FAQs
• King's Schoolroom
• Play and Youth Team
• Cash machines
• Shops and cafes
• Smoke-free King's
• WiFi and entertainment
• Find a relative
• Letters to Loved Ones email service
• Preventing infection
• Wards A to C
• Wards D to F
• Wards G to I
• Wards J to L
• Wards M to O
• Wards P to R
• Wards S to U
• Wards V to Z
• Participating in a study
• 100,000 Genomes Project
• Clinical Age Research Unit Publications
• HIV Research Centre
• Liver Intensive Therapy Unit Research Database
• Management of People with Chronic Liver Disease
• King's Ophtalmology Research Unit
• The Bridging the Gap Study
• Integrated Research Application System (IRAS)
• Local approvals
• National approvals
• Conducting your research
• Contact the Research Office
• Feasibility review
• Finalising your research
• Initial planning
• Sponsorship and Peer Review
• Use of data for research and innovation
• Brain and spine cancer
• Breast cancer
• Colorectal cancer
• Gynaecological cancers
• Head and neck cancers
• Hepatobiliary pancreatic cancers
• Liver cancer (primary)
• Lung cancer
• Myeloid (leukaemia)
• Myeloma (blood cancer)
• Neuroendocrine cancers
• Skin cancers
• Thyroid cancer
• Upper gastrointestinal cancers
• Urological cancers
• Contact the cancer team
• Coping with symptoms and treatments
• Benefits advice
• Diet and nutrition
• Free prescriptions
• Health and wellbeing information and support
• King’s Macmillan Information and Support Centre
• Palliative care
• Personalised follow-up after treatment
• Physiotherapy
• Psychological support
• Support groups and clinics
• Patient Information Leaflets
• Referrals for children and young people
• Blood tests
• Nuclear medicine scan
• PET-CT scan
• Chemotherapy
• CAR T therapy
• Radiotherapy
• Guy's and St Thomas'
• King's Health Partners
• Macmillan Cancer Support
• National Cancer Patient Experience Survey
• South East London Cancer Alliance
• Turning research into treatments
• Your clinical nurse specialist (CNS)
• Your multidisciplinary team (MDT)
• Accessibility statement
• Cookie information
• Website terms and conditions

Services A to Z

• Accident and Emergency (A&E)
• Acute Dental Care
• Acute Medicine
• Adrenal surgery
• Advanced chronic liver disease (cirrhosis)
• Allergy and immunology
• Allergy, children
• Anal cancer
• Ankyloglossia
• Antenatal care
• Antenatal scanning
• Antibiotics IV at home
• Asthma, children
• Bariatric dentistry
• Bereavement support
• Bile duct cancer
• Biliary atresia
• Biliary cancer
• Bleeding disorders
• Blood cancer
• Blood disorders
• Blood disorders, children
• Blood transfusions
• Bone marrow transplantation
• Bowel cancer
• Bowel Cancer Screening
• Bowel disorders, children
• Brain surgery, children
• Brain tumours
• Breast Care Unit
• Breast Screening
• Breast surgery
• Breathing disorders, adults
• Breathing disorders, children
• Breathing tests
• Bronchoscopy
• Camberwell Sexual Health Centre
• Cancer, adults
• Cancer, children
• Cardiac health and rehabilitation
• Cardiac investigations
• Cardiac non-invasive diagnostics
• Cardiac Rehabilitation
• Cardiothoracic surgery
• Cervical cancer
• Chemotherapy Day Unit
• Chest disorders
• Chest Unit and Lung Function
• Children’s dentistry
• Children’s Emergency Department
• Children’s services
• Clinical gerontology
• Coagulation medicine
• Colorectal liver metastases
• Colorectal surgery
• Colposcopy and Vulvoscopy
• Community dental service
• Community heart failure service
• Community Special Care Dentistry
• Complications of excess weight (CEW)
• Contraception
• Craniofacial prosthetics
• CT, general
• Cystic fibrosis, adult
• Cystic fibrosis, children
• Deep brain stimulation (DBS)
• Denmark Hill Clinic
• Dental – acute
• Dental – community special care dentistry
• Dental – hospital based bariatric dentistry
• Dental – hospital based special care dentistry
• Dental and facial orthodontics
• Dental care, children
• Dermatology
• Diverticular disease
• Doppler scanning
• Duplex scanning
• Early Pregnancy Unit
• EEG (electroencephalography) Video Telemetry
• Elderly care
• Electromyography (EMG)
• Emergency dental care
• Emergency Department
• Endocrine gynaecology
• Endocrine surgery
• Endocrinology
• Endocrinology, children
• Endovascular neurosurgery
• Endovascular surgery
• Epilepsy, children
• Eye conditions
• Eye conditions, children
• Facial prosthetics
• Facial surgery
• Fetal cardiology
• Fetal medicine
• Fetal scanning
• Fracture care team
• Frank Cooksey Rehabilitation Unit
• Gastroenterology
• Gastrointestinal disorders, children
• Gastroscopy
• General gynaecology
• General imaging
• General neurology
• General paediatrics
• Geriatric medicine
• Gynae ultrasound
• Gynae-oncology
• Gynaecology – Colposcopy clinic
• Gynaecology – endocrine
• Gynaecology – general
• Gynaecology – Menopause clinic
• Gynaecology – rapid access clinics
• Haemato-oncology
• Haematology
• Haematology, children
• Haemodialysis
• Harris Birthright Centre
• Head injury, children
• Heart failure
• Heart Failure – Integrated Community Service
• Heart investigations
• Heart rehab
• Heart surgery
• Hepatobiliary and pancreatic (HPB)
• Home Video Telemetry
• Hormonal disorders, children
• Hormonal disorders, women
• Hormone disorders, general
• Imaging, general
• Imaging, neuro
• Immunodeficiency
• Infertility
• Insulin restriction
• Integrated heart failure service – community
• Interventional neuroradiology
• IV antibiotics at home
• Kidney disease
• Liver disease
• Liver disease, children
• Liver transplantation
• Lung disorders
• Lung Function
• Macmillan care, End of life
• Maxillofacial prosthetics and reconstruction
• Maxillofacial surgery
• Metabolic muscle disease
• Metastatic Spinal Cord Compression (MSCC)
• Motor nerve
• Motor neurone disease (MND)
• Mouth disorders
• Mouth surgery
• Movement disorders
• MRI, general
• Multiple sclerosis (MS)
• Muscle and myasthenia
• Musculoskeletal outpatient physiotherapy
• Myeloid cancer
• Nerve Conduction and Electromyography
• Nerve Conduction Studies (NCS)
• Nervous system disorders
• Neuro-oncology
• Neuro-rehabilitation
• Neuroendocrine tumours (NETs)
• Neurointerventional radiology
• Neurology, children
• Neurology, general
• Neuromuscular
• Neuropsychology
• Neuroradiology
• Neurosciences
• Neurosurgery
• Neurotelemetry
• Neurovascular
• Nuclear medicine
• Occupational therapy
• Older people, care
• Ophthalmology
• Ophthalmology, children
• Oral and maxillofacial surgery
• Oral medicine
• Oral surgery
• Orthodontics
• Orthopaedics and trauma
• Outpatient IV antibiotics
• Outpatient Parenteral Antimicrobial Therapy (OPAT)
• Paediatric allergy
• Paediatric cystic fibrosis
• Paediatric dentistry
• Paediatric Emergency Department
• Paediatric endocrinology
• Paediatric gastroenterology and nutrition
• Paediatric haematology
• Paediatric liver
• Paediatric neurology
• Paediatric oncology
• Paediatric ophthalmology
• Paediatric orthopaedics
• Paediatric respiratory
• Paediatric sickle cell and thalassaemia
• Paediatric surgery
• Paediatrics, general
• Pain management
• Pancreas disorders, children
• Pancreatic cancer
• Parkinson’s and movement disorders
• Peripheral nerve
• PET-CT scans
• Physiotherapy – Musculoskeletal outpatients
• Postnatal care
• Programmed Investigation Unit (PIU)
• Psychology (Adult Clinical Health)
• Psychosexual support
• Pulmonary function tests
• Pulmonary rehabilitation
• Radiology, general
• Radiology, neuro
• Radionuclide therapy
• Rainbow Clinic
• Rape clinic
• Rapid Access Chest Pain Clinic
• Red cell haematology
• Respiratory medicine
• Restorative dentistry
• Rheumatology
• Scans, antenatal
• Scans, general
• Scans, gynae
• Scans, neuro
• Sexual Assault Referral Centre (SARC)
• Sexual health
• Sickle cell, adult
• Sickle cell, children
• Skin allergy, children
• Skin cancer
• Skin problems
• Sleep studies
• South East London Breast Screening Programme
• Special Care Baby Unit (SCBU)
• Special care dentistry – community
• Special care dentistry – hospital based
• Specialist Sexual Health Service
• Speech and language therapy
• Spinal surgery
• Spinal surgery, children
• Stroke medicine
• Surgery, children
• Telemetry, neuro
• Termination of pregnancy
• Thalassaemia, adult
• Thalassaemia, children
• Thrombosis and haemostasis
• Thyroid disorders
• Thyroid surgery
• Transient Ischaemic Attack (TIA)
• Type 1 Diabetes with Disordered Eating (T1DE)
• Ultrasound, antenatal
• Ultrasound, general
• Ultrasound, general gynae
• Ultrasound, vascular
• Urgent dental clinic
• Urogynaecology
• Vascular Access Team
• Vascular and endovascular surgery
• Vascular ultrasound
• Video-EEG telemetry
• Viral hepatitis
• X-ray, general
• X-ray, neuro

• Create online account

King’s College Hospital

Location of laboratory.

Denmark Hill, London

South London Specialist Virology Centre Kings College Hospital NHS Foundation Trust 2nd floor Cheyne Wing Bessemer Road Denmark Hill, London SE5 9RS

TELEPHONE & FAX NUMBER

Clinical Advice: 0203 299 6978 Enquiries: 0203 299 6155/6

WHAT DO WE DO?

King’s College Hospital NHS Foundation Trust provides a wide range of services to the population of South East London. The Trust serves Lambeth, Southwark and Lewisham with a population of 700,000.

King’s College Hospital is a teaching hospital and centre of excellence with 950 in-patient beds, several specialist units of international repute, and units offering regional or supra-regional services within the Denmark Hill site. On 1st October 2013 South London Healthcare NHS Trust was dissolved and parts of it were acquired by King’s College Hospital NHS Foundation Trust. The Princess Royal University Hospital (PRUH) is in Farnborough, near Orpington, Kent. Beckenham Hospital is about 6 miles to the north of the PRUH and provides outpatient services. Orpington Hospital is 3 miles south of PRUH and provides outpatient services and has 40 intermediate care beds.

The enlarged Trust is located on multiple sites serving the economically diverse boroughs of Southwark, Lambeth and Bromley and Bexley. As both a major employer with over 10,500 staff we play an important part in helping reduce local, social and health inequalities. The enlarged Trust has an annual income of around £800m, around half of which is derived from Clinical Commissioning Groups. The Trust is embarking on a strategy to achieve greater diversification of its income, with growth anticipated in tertiary referrals, research and commercial services activities. There is also a developing fund raising partnership within King’s Health Partners.

King’s College Hospital NHS Foundation Trust has an enviable track record in research and development and service innovation. In partnership with King’s College London the Trust has recently been awarded a National Research Centre in Patient Safety and Service Quality. It is also a partner in two National Institute for Health Research Biomedical Research Centres. The first is a Comprehensive centre with King’s College London and Guy’s and St Thomas’s NHS Foundation Trust and the second is a Specialist centre with the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry. King’s College Hospital NHS Foundation Trust has also recently strengthened its research and development infrastructure in order better to support clinical researchers across the organisation.

Dr Mark Zuckerman

Consultant Virologist, Head of Department

Dr Malur Sudhanva

Consultant Virologist

Dr Temi Lampejo

Consultant in Virology and Infectious Diseases

Dr Melvyn Smith

Principal Clinical Scientist

Interim Service Delivery Manager

Dr Colleen Gilkes

Operations Manager

Dr Gulrukh Ahsan

Quality Manager

15 November 2023

New psychedelics and mental health research centre officially opens

The Centre for Mental Health Research and Innovation officially opened on 15 November 2023 to accelerate research into psychedelics and develop new models of care for mental health.

The new Centre is part of a pioneering long-term strategic partnership between biotechnology company Compass Pathways , South London and Maudsley NHS Foundation Trust, and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.

Located at the Maudsley Hospital in South London, the dedicated and purpose-built space will be run by leading clinical investigators, Professor Allan Young, Head of Academic Psychiatry at IoPPN, and Dr James Rucker, Consultant Psychiatrist and Lead of the Psychoactive Trials Group at King’s College London. The centre’s research will initially focus on areas of urgent need, including treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa.

Professor Allan Young said, “Today marks a milestone for research into the use of psychedelics to treat mental health conditions. Over several years we have moved to phase 3 clinical trials for psilocybin and treatment-resistant depression, an achievement that would not have been possible without the facilities and staff of the NIHR King’s Clinical Research Facility.

Now with this new Centre, the continuing partnership between Compass Pathways, King’s College London and South London and Maudsley is embarking on the next stage of research where we can evaluate the safety and effectiveness of psychedelics to treat a range of mental health conditions, explore the mechanisms behind how psychedelics might work and assess the feasibility for their delivery at scale. Professor Allan Young, Head of Academic Psychiatry, IoPPN

Coinciding with the Centre opening, Compass Pathways announced the commencement of the UK component of its phase 3 program of the use of psilocybin in treatment-resistant depression (TRD). The research will take place in multiple sites in the UK, including at the Centre for Mental Health Research and Innovation. The on-going phase 3 program is the largest randomised, controlled, double-blind psilocybin treatment clinical program ever conducted, and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.

David Bradley, Chief Executive of South London and Maudsley NHS Foundation Trust, said, “We are excited to be running part of this pivotal phase 3 study at the new Centre for Mental Health Research at our Maudsley Hospital site in south London.”

This partnership shows how working across academia, the NHS and industry can accelerate the development of exciting new treatments for mental disorders. Early stage support from funders such as the NIHR make it possible to establish the potential of novel treatments so we can work between partners in different sectors to find better treatments, which are so badly needed. The new Centre will help accelerate the development of new much-needed therapies. Professor Matthew Hotopf CBE, Executive Dean at IoPPN

The newly launched Centre is part of a research partnership which will help to develop innovative treatment with the goal of improving mental health care for people across the UK. Our world-leading clinicians will work closely with researchers at the new Centre and will begin with a focus on areas of urgent need, such as post- traumatic stress disorder, anorexia nervosa and treatment-resistant depression. David Bradley, Chief Executive of South London and Maudsley NHS Foundation Trust

The Centre will assist in the development of new models of care to help integrate these investigational treatments into healthcare systems, if approved in the future. This will include evaluating real-world evidence, researching and developing digital technologies that may help to deliver personalised, predictive and preventative care models, and conducting therapist training.

“Every 40 seconds, someone dies from suicide; tens of millions more live with mental health conditions for which there is no good standard of care.” said Kabir Nath, CEO, Compass Pathways. “The launch of our phase 3 clinical study in treatment-resistant depression here in the UK is an important step in developing innovations that are urgently needed, and we recognize the important role that public-private partnerships play in this."

"We’re proud to partner with South London and Maudsley NHS Foundation Trust and King’s College London to open the new Centre for Mental Health Research and Innovation. Together, we are conducting cutting-edge research to develop new solutions for mental illnesses and ensure these potential treatments are broadly and equitably accessible to those who need them the most.”

The psychoactive trials group based at the IoPPN brings together researchers and clinicians from King’s College London and South London and Maudsley to study psychedelics as a treatment for a range of mental health conditions including TRD, anorexia and PTSD. Much of this research has taken place at the National Institute of Health and Care Resaerch (NIHR) King’s Clinical Research Facility and been supported by NIHR Maudsley Biomedical Research Centre , whose interim director Professor Grainne McAlonan is leading an investigative study into psilocybin and autism.

For more information, please contact the IoPPN Communications Team .

In this story

Professor Allan Young

Head of School, Academic Psychiatry

James Rucker

Consultant Psychiatrist & Senior Clinical Lecturer

Related departments

• Institute of Psychiatry, Psychology & Neuroscience
• School of Academic Psychiatry
• Centre for Affective Disorders (CfAD)